Alzheimer's disease: Recent advances and future perspectives

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Ubhi, Kiren ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; chaperone; dementia; immunotherapy; neurotrophic factors; transgenic

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BECLIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CHAPERONE; PEPTIDE VACCINE; TAR DNA BINDING PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AUTOPHAGY; CLEARANCE; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

EID: 84871721526     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129028     Document Type: Review

References (110)

1. Maslow K (2010) 2010 Alzheimer's disease facts and figures. Alzheimers Dement 6, 158-194
2. SelkoeD(1989) Amyloid protein precursor and the pathogenesis of Alzheimer's disease. Cell 58, 611-612
3. Selkoe D (1990) Amyloid -Protein deposition as a seminal pathogenic event in AD: An hypothesis. Neurobiol Aging 11, 299
4. Selkoe D (1993) Physiological production of the -Amyloid protein and the mechanisms of Alzheimer's disease. Trends Neurosci 16, 403-409
5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-Associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917
6. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubuleassociated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83, 4044-4048
7. Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-Associated protein tau (tau). Proc Natl Acad Sci U S A 83, 4040-4043
8. DeKosky S, Scheff S (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464
9. DeKosky ST, Scheff SW, Styren SD (1996) Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 5, 417-421
10. Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R, Hansen L, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580
11. Klucken J, McLean PJ, Gomez-Tortosa E, Ingelsson M, Hyman BT (2003) Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res 28, 1683-1691
12. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT (2009) Tau pathophysiology in neurodegeneration: A tangled issue. Trends Neurosci 32, 150-159
13. Sisodia S, Price D (1995) Role of the beta-Amyloid protein in Alzheimer's disease. FASEB J 9, 366-370
14. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-Level neuronal expression of abeta 1-42 in wild-Type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058
15. Perez M, Moran MA, Ferrer I, Avila J, Gomez-Ramos P (2008) Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. Acta Neuropathol 116, 409-418
16. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E (2010) Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 277, 3051-3067
17. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20, 814-822
18. Glabe CC (2005) Amyloid accumulation and pathogensis of Alzheimer's disease: Significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38, 167-177
19. Klein WL (2002) Abeta toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352
20. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224
21. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11, 213-228
22. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T (2006) Deficiency in neuronal TGFbeta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 116, 3060-3069
23. Flanders KC, Ren RF, Lippa CF (1998) Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 54, 71-85
24. Unsicker K, Krieglstein K (2002) TGF-betas and their roles in the regulation of neuron survival. Adv Exp Med Biol 513, 353-374
25. Brionne TC, Tesseur I, Masliah E, Wyss-Coray T (2003) Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40, 1133-1145
26. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB (1995) Altered expression of transforming growth factorbeta in Alzheimer's disease. Neurology 45, 1561-1569
27. De Servi B, La Porta CA, Bontempelli M, Comolli R (2002) Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp Gerontol 37, 813-821
28. Wyss-CorayT, Lin C,Yan F,Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 7, 612-618
29. Frautschy SA, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular beta-Amyloid in rat brains injected with Alzheimer beta-Amyloid. Am J Pathol 140, 1389-1399
30. Magnus T, Chan A, Linker RA, Toyka KV, Gold R (2002) Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: Implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol 61, 760-766
31. Ueberham U, Ueberham E, Bruckner MK, Seeger G, Gartner U, Gruschka H, Gebhardt R, Arendt T (2005) Inducible neuronal expression of transgenic TGF-beta1 in vivo: Dissection of short-Term and long-Term effects. Eur J Neurosci 22, 50-64
32. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L (1997) Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389, 603-606
33. Grammas P, Ovase R (2002) Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 160, 1583-1587
34. Dolan PJ, Johnson GV (2010) The role of tau kinases in Alzheimer's disease. Curr Opin Drug DiscovDevel 13, 595-603
35. CarterMD,Simms GA,WeaverDF(2010) The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Therap 88, 475-486
36. Medina M, Avila J (2010) Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 16, 2790-2798
37. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27, 1981-1991
38. Wilson AC, Dugger BN, Dickson DW, Wang DS (2011) TDP-43 in aging and Alzheimer's disease - A review. Int J Clin Exp Pathol 4, 147-155
39. Chen-Plotkin AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6, 211-220
40. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20, 1774-1784
41. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67, 555-564
42. Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW (2007) Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol 113, 245-252
43. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 61, 435-445
44. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118, 5-36
45. Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S,Yusuf I, Amin H, Duplessis D, Troakes C, Al-Sarraj S, Sloan C, Esiri MM, Prasher VP, Allsop D, Neary D, Pickering-Brown SM, Snowden JS, Mann DM (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's Syndrome: Association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122, 703-713
46. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, Masliah E, Kaye J, Clark CM, Montine TJ, Lee VM, Trojanowski JQ (2007) Co-Morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114, 221-229
47. Martin L, Latypova X, Terro F (2011) Post-Translational modifications of tau protein: Implications for Alzheimer's disease. Neurochem Int 58, 458-471
48. De Kimpe L, Scheper W (2010) From alpha to omega with Abeta: Targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. Curr Med Chem 17, 198-212
49. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086
50. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, et al. (1994) Relative abundance of AlzheimerAbeta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91, 8378-8382
51. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG (2000) Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276, 422-427
52. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-Amyloid peptides (in vitro). Biochemistry 45, 12393-12399
53. HeW, BarrowCJ (1999) TheAbeta 3-Pyroglutamyl and 11-Pyroglutamyl peptides found in senile plaque have greater beta-Sheet forming and aggregation propensities in vitro than full-Length A beta. Biochemistry 38, 10871-10877
54. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-Amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457-466
55. Chung SH (2009) Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 42, 467-474
56. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53-69
57. GoedertM(2005) Tau gene mutations and their effects. Mov Disord 20(SUPPL12), S45-S52
58. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119
59. Johnson GV, Stoothoff WH (2004) Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117, 5721-5729
60. Mandelkow E, von Bergen M, Biernat J, Mandelkow EM (2007) Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17, 83-90
61. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 777, 96-106
62. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739, 216-223
63. Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis 9, 195-207
64. Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, Morbin M, Primavera A, Carella F, Solaro C, Grisoli M, Savoiardo M, Spillantini MG, Tagliavini F, Goedert M, Ghetti B (1999) Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 58, 667-677
65. Frank S, Clavaguera F, Tolnay M (2008) Tauopathy models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 39-53
66. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159
67. Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, IharaY(1992) Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem 267, 17047-17054
68. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA (2006) S-Nitrosylated protein-Disulphide isomerase links protein misfolding to neurodegeneration. Nature 441, 513-517
69. Moreira PI, Santos RX, Zhu X, Lee HG, Smith MA, Casadesus G, Perry G (2010) Autophagy in Alzheimer's disease. Expert Rev Neurotherap 10, 1209-1218
70. Nixon RA,Wegiel J,Kumar A,YuWH,PeterhoffC, Cataldo A, Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol 64, 113-122
71. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, Nixon RA (2005) Macroautophagy-A novel Beta-Amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171, 87-98
72. Hung SY, Huang WP, Liou HC, Fu WM (2009) Autophagy protects neuron from Abeta-induced cytotoxicity. Autophagy 5, 502-510
73. Wang H, Ma J, Tan Y, Wang Z, Sheng C, Chen S, Ding J (2010) Amyloid-beta1-42 induces reactive oxygen speciesmediated autophagic cell death in U87 and SH-SY5Y cells. J Alzheimers Dis 21, 597-610
74. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM,Wolfe DM, Martinez-Vicente M, MasseyAC, SovakG, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158
75. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I,Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC (2006) Rapamycin alleviates toxicity of different aggregate-Prone proteins. Hum Mol Genet 15, 433-442
76. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum Mol Genet 18, 4153-4170
77. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2010) Synergy and antagonism of macroautophagy and chaperonemediated autophagy in a cell model of pathological tau aggregation. Autophagy 6, 182-183
78. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 285, 13107-13120
79. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118, 2190-2199
80. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S (2001) Reduced levels of amyloid beta-Peptide antibody in Alzheimer disease. Neurology 57, 801-805
81. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 410, 90-93
82. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N,Weiss K,Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-Peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919
83. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, HoltzmanDM(2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98, 8850-8855
84. Kokjohn TA, Roher AE (2009) Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 8, 88-97
85. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M (2009) Long-Term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 6, 144-151
86. Asuni AA, Boutajangout A, Quartermain D, SigurdssonEM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115-9129
87. Sigurdsson EM, Quartermain D, Boutajangout A (2008) Tau immunotherapy prevents cognitive decline and clears pathological tau in a tangle mouse model. Alzheimers Dement 4, T191
88. Chao MV, Rajagopal R, Lee FS (2006) Neurotrophin signalling in health and disease. Clin Sci 110, 167-173
89. Capsoni S, CattaneoA(2006)Onthe molecular basis linking nerve growth factor (NGF) to Alzheimer's disease. Cell Mol Neurobiol 26, 619-633
90. Zuccato C, Cattaneo E (2009) Brain-Derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5, 311-322
91. Siegel GJ, Chauhan NB (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 33, 199-227
92. Lad SP, Neet KE, Mufson EJ (2003) Nerve growth factor: Structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2, 315-334
93. Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson's disease. Prog Brain Res 175, 201-216
94. Saragovi HU, Hamel E, Di Polo A (2009) A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr Alzheimer Res 6, 419-423
95. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-Derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15, 331-337
96. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I (2007) Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 28, 1148-1162
97. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor-Like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7, 213-221
98. Francis-Turner L,ValouskovaV(1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: Short-Term study. Neurosci Lett 202, 193-196
99. Francis-Turner L, Valouskova V, Mokry J (1996) The longterm effect of NGF, b-FGF and Cerebrolysin on the spatial memory after fimbria-fornix lesion in rats. J Neural Transm SUPPL47, 277
100. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E (2005) Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm 112, 269-282
101. Rockenstein E, Adame A, Mante M, Moessler H,Windisch M, Masliah E (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110, 1313-1327
102. Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E (2002) Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl, 327-336
103. Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, Trejo M, Crews L, Paulino A, Moessler H, Masliah E (2009) Neurofibrillary and neurodegenerative pathology in APP-Transgenic mice injected with AAV2-Mutant TAU: Neuroprotective effects of Cerebrolysin. Acta Neuropathol 117, 699-712
104. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H (2006) A 24-week, double-blind, placebocontrolled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13, 43-54
105. Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M (2000) Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 107, 815-829
106. Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27, 32-40
107. Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H (2011) Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol 18, 59-68
108. Plosker GL, Gauthier S (2010) Spotlight on cerebrolysin in dementia. CNS Drugs 24, 263-266
109. Plosker GL, Gauthier S (2009) Cerebrolysin: A review of its use in dementia. Drugs Aging 26, 893-915
110. Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E (2011) Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. J Neurosci Res 89, 1812-1821